Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance

Baseline Data Show More Frequent Selection of Ibalizumab in Patients with Lower CD4 Counts and Higher Viral Loads, Compared to Other Regimens Read More

Ads Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute
Bipsync and Dasseti Partner to Streamline Research and Due Diligence Processes for Investment Management
Vultr Unveils Advanced Serverless Capabilities for Agentic AI for the Enterprise

Carlisle Companies to Acquire Plasti-Fab, a Canadian Based Vertically Integrated Manufacturer of Expanded Polystyrene Insulation Products
Cartier Drill Results on Globex Royalty Claims